Venous thromboembolism in patients with membranous nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 43-51

  Lionaki, Sophia ^a,b   Derebail, Vimal K ^b   Hogan, Susan L ^b   Barbour, Sean ^c   Lee, Taewoo ^b   Hladunewich, Michelle ^c   Greenwald, Allen ^c   Hu, Yichun ^b   Jennette, Caroline E ^b   Charles Jennette, J ^b   Falk, Ronald J ^b   Cattran, Daniel C ^c   Nachman, Patrick H ^b   Reich, Heather N ^c  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTICOAGULANT AGENT; AZATHIOPRINE; CHLORAMBUCIL; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPYRIDAMOLE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; WARFARIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEMBRANOUS GLOMERULONEPHRITIS; PROTEINURIA; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84863115996     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04250511     Document Type: Article

References (48)

1. Bellomo R, Atkins RC: Membranous nephropathy and throm-boembolism: Is prophylactic anticoagulation warranted? Nephron 63: 249-254, 1993
2. Llach F, Papper S, Massry SG: The clinical spectrum of renal vein thrombosis: Acute and chronic. Am J Med 69: 819-827, 1980
3. Chugh KS, Malik N, Uberoi HS, Gupta VK, Aggarwal ML, Singhal PC, Suri S, Jain SK: Renal vein thrombosis innephrotic syndrome- A prospective study and review. Postgrad Med J 57: 566-570, 1981
4. Wagoner RD, Stanson AW, Holley KE, Winter CS: Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: Incidence and significance. Kidney Int 23: 368-374, 1983
5. Velasquez Forero F, Garcia Prugue N, Ruiz Morales N: Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 8: 457-462, 1988
6. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324-332, 2003
7. Singhal R, Brimble KS: Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res 118: 397-407, 2006
8. Coggins CH: Is membranous nephropathy treatable? Am J Nephrol 1: 219-221, 1981
9. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN: Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. [published online ahead of print September 14, 2011] Kidney Int doi:10.1038/ki.2011.312
10. Falk RJ, Hogan SL, Muller KE, Jennette JC: The Glomerular Disease Collaborative Network: Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophospha-mide and corticosteroids with corticosteroids alone. [See comments] Ann Intern Med 116: 438-445, 1992
11. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S: Canadian Glomerulonephritis Study Group: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130- 1135, 1995
12. Ibrahim H, Mondress M, Tello A, Fan Y, Koopmeiners J, Thomas W: An alternative formula to the Cockcroft-Gault and the modification of diet in renal diseases formulas in predicting GFR in individuals with type 1 diabetes. J Am Soc Nephrol 16: 1051-1060, 2005
13. Perez A, Bartholomew JR: Interpreting the JUPITER trial: Statins can prevent VTE, but more study is needed. Cleve Clin J Med 77: 191-194, 2010
14. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM: A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851-1861, 2009
15. Squizzato A, Romualdi E, Ageno W: Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost 4: 1925-1927, 2006
16. Kendall AG, Lohmann RC, Dossetor JB: Nephrotic syndrome. A hypercoagulable state. Arch Intern Med 127: 1021-1027, 1971
17. Noel LH, Zanetti M, Droz D, Barbanel C: Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 66: 82-90, 1979
18. Llach F, Arieff AI, Massry SG: Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients. Ann Intern Med 83: 8-14, 1975
19. Llach F, Koffler A, Finck E, Massry SG: On the incidence of renal vein thrombosis in the nephrotic syndrome. Arch Intern Med 137: 333-336, 1977
20. Mahmoodi BK, Ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J: High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. Circulation 117: 224-230, 2008
21. Chen M, Zhou FD, Zhao MH, Wang HY: Normoalbuminaemia is associated with IgA nephropathy in primary glomerulopathy with nephrotic-range proteinuria in Chinese patients. Nephrol Dial Transplant 26: 1247-1252, 2011
22. Rostoker G, Behar A, Lagrue G: Vascular hyperpermeability in nephrotic edema. Nephron 85: 194-200, 2000
23. Kanfer A, Kleinknecht D, Broyer M, Josso F: Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 24: 562-571, 1970
24. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA: Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. AmJ Med65: 607-613, 1978
25. Thomson C, Forbes CD, Prentice CR, Kennedy AC: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med43: 399-407, 1974
26. Boneu B, Bouissou F, Abbal M, Sie P, Caranobe C, Barthe P: Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome. Thromb Haemost 46: 623-625, 1981
27. Vaziri ND, Toohey J, Paule P, Alikhani S, Hung E: Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. IntJ Artif Organs 7: 323-326, 1984
28. McGinley E, Lowe GD, Boulton-Jones M, Forbes CD, Prentice CR: Blood viscosity and haemostasis in the nephrotic syndrome. Thromb Haemost 49: 1 55-157, 1983
29. Rydzewski A, Mysliwiec M, Soszka J: Concentration of three thrombin inhibitors in the nephrotic syndrome in adults. Nephron 42: 200-203, 1986
30. Kauffmann RH, de Graeff J, de la Riviere GB, van Es LA: Unilateral renal vein thrombosis and nephrotic syndrome. Report of a case with protein selectivity and antithrombin III clearance studies. Am J Med 60: 1048-1054, 1976
31. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ: Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest93:204-211,1994
32. Hamano K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, Dohi K: Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 39: 695-705, 2002
33. Remuzzi G, Mecca G, Marchesi D, Livio M, de Gaetano G, Donati MB, Silver MJ: Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1 6: 345-354, 1979
34. Sirolli V, Ballone E, Garofalo D, Merciaro G, Settefrati N, Di Mascio R, Di Gregorio P, Bonomini M: Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron 91: 424-430, 2002
35. Yoshida N, Aoki N: Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 52: 969-977, 1978
36. Jackson CA, Greaves M, Patterson AD, Brown CB, Preston FE: Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 52: 69-77, 1982
37. Schieppati A, Dodesini P, Benigni A, Massazza M, Mecca G, Remuzzi G, Livio M, de Gaetano G, Rossi EC: The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int 25: 671-676, 1984
38. Holst AG, Jensen G, Prescott E: Risk factors for venous thromboembolism: Results from the Copenhagen City Heart Study. Circulation 121:1 896-1903, 2010
39. Severinsen MT, Overvad K, Johnsen SP, Dethlefsen C, Madsen PH, Tjønneland A, Kristensen SR: Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol 149: 273-279, 2010
40. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: A prospective study of risk factors for pulmonary embolism in women. JAMA 277: 642- 645, 1997
41. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, Leydon GM: A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49: 580-590, 2000
42. Pomp ER, Rosendaal FR, Doggen CJ: Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 83: 97-102, 2008
43. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K: Anthropometry, body fat, and venous thromboembolism: A Danish follow-up study. Circulation 120: 1850-1857, 2009
44. Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578-585, 1994
45. Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G: Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 25: 75-80, 1986
46. Hayes MJ, Langman MJ, Short AH: Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins. Br J Clin Pharmacol 2: 69-72, 1975
47. Bennett WM, Nicholls K, Kincaid-Smith P: Clinicopathological associationsin mesangialIgAnephropathy.Am JNephrol 7:166-167, 1987
48. Morrison GW: Predicting warfarin requirements. Lancet 1: 553, 1979